Urothelial Carcinoma Treatment Market Size & Share, by Treatment (Immunotherapy, Radiotherapy, Chemotherapy); End-user (Hospital Pharmacy, Retail Pharmacy); Type (Non-Invasive, Invasive Urothelial Carcinoma) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 3912
  • Published Date: Mar 01, 2023
  • Report Format: PDF, PPT

Companies Dominating the Urothelial Carcinoma Treatment Landscape

top-features-companies
    • Pfizer, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • GlaxoSmithKline plc
    • Novartis AG
    • Dendreon Pharmaceuticals LLC
    • Sanofi SA
    • F. Hoffmann-La-Roche AG
    • UroGen Pharma Ltd
    • Koninklijke Philips N.V.
    • Olympus Corporation
    • AstraZeneca PLC

Browse Key Market Insights with Data Illustration:

In-the-news

In The News

  • Olympus Corporation announced a binding agreement to purchase London-based cloud-AI endoscopy business Odin Vision, which offers a wide range of commercially available computer-aided detection/diagnostic (CAD) solutions. With the agreement, Olympus is able to provide cutting-edge AI-powered solutions and data-driven insights that improve clinical and procedural procedures and change patient care.

  • Sanofi SA licensed an NK cell engager program from Innate's ANKETTM (Antibody-based NK Cell Engager Therapies) technology that targets B7H3. This extended partnership with Innate Pharma will enable Sanofi to have the option of including up to two more ANKETTM targets, and be in control of all development, manufacture, and marketing.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 3912
  • Published Date: Mar 01, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Raising funding for research and development to develop novel cancer therapies and the growing awareness about bladder diseases are the major factors driving the market growth.

The market is anticipated to attain a CAGR of 21% over the forecast period, i.e., 2023-2035.

Adverse effects of chemotherapy and the expensive equipment needed for urothelial carcinoma therapy are estimated to be the growth hindering factors for the market expansion.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are GlaxoSmithKline plc, Novartis AG, Dendreon Pharmaceuticals LLC, Sanofi SA, F. Hoffmann-La-Roche AG, UroGen Pharma Ltd, Koninklijke Philips N.V., Olympus Corporation, AstraZeneca PLC, and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by type, treatment, end user, and by region.

The chemotherapy segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying